Page last updated: 2024-08-22

hafnium and Sarcoma

hafnium has been researched along with Sarcoma in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	6 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Balosso, J; Chargari, C; Porcel, E; Rodriguez-Lafrasse, C; Verry, C	1
Bourhis, J; Jumeau, R; Vilotte, F	1
Bonvalot, S; Le Péchoux, C; Wardelmann, E	1
Khalladi, N; Thariat, J	1
Nussbaum, DP	1
Agoston, P; Anghel, R; Austen, L; Bonvalot, S; Borkowska, A; Bovée, JVMG; Carrère, S; Co, A; de Baère, T; Dema, S; Ducassou, A; Gebhart, M; Gronchi, A; Helfre, S; Herraez, AC; Hohenberger, P; Hong, A; Kacso, G; Kantor, G; Lapeire, L; Lazar, AJ; Le Cesne, A; Le Péchoux, C; Li, RK; Loong, HH; Mangel, L; Mervoyer, A; Montero, A; Moreno, V; Moureau-Zabotto, L; Papai, Z; Rastrelli, M; Rutkowski, PL; Saada-Bouzid, E; Servois, V; Sunyach, MP; Sy-Ortin, T; Terrier, P; Thariat, J; Tiangco, B; Vergés, R; Wardelmann, E	1

Reviews

1 review(s) available for hafnium and Sarcoma

Article	Year
[Use of nanoparticles as radiosensitizing agents in radiotherapy: State of play]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2019, Volume: 23, Issue:8 Topics: Adenocarcinoma; Brain Neoplasms; Clinical Trials, Phase I as Topic; Gadolinium; Gold; Hafnium; Humans; Lung Neoplasms; Nanomedicine; Nanoparticles; Radiation-Sensitizing Agents; Sarcoma	2019

Trials

1 trial(s) available for hafnium and Sarcoma

Article	Year
NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. The Lancet. Oncology, 2019, Volume: 20, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Female; Hafnium; Humans; Male; Middle Aged; Nanoparticles; Oxides; Radiation-Sensitizing Agents; Radiotherapy; Sarcoma; Soft Tissue Neoplasms; Young Adult	2019

Article

Year

NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial.

The Lancet. Oncology, 2019, Volume: 20, Issue:8

Topics: Adult; Aged; Aged, 80 and over; Female; Hafnium; Humans; Male; Middle Aged; Nanoparticles; Oxides; Radiation-Sensitizing Agents; Radiotherapy; Sarcoma; Soft Tissue Neoplasms; Young Adult

2019

Other Studies

4 other study(ies) available for hafnium and Sarcoma

Article	Year
High Z nanoparticles and radiotherapy: a critical view. The Lancet. Oncology, 2019, Volume: 20, Issue:10 Topics: Hafnium; Humans; Nanoparticles; Oxides; Sarcoma	2019
High Z nanoparticles and radiotherapy: a critical view - Authors' reply. The Lancet. Oncology, 2019, Volume: 20, Issue:10 Topics: Hafnium; Humans; Nanoparticles; Oxides; Sarcoma	2019
[Doubling complete histological response in sarcomas with radiation therapy using nanoparticles (Hafnium oxide, NBTXR3), a phase III trial]. Bulletin du cancer, 2019, Volume: 106, Issue:12 Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Dose Fractionation, Radiation; Hafnium; Humans; Multicenter Studies as Topic; Nanoparticles; Organs at Risk; Oxides; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Risk Assessment; Sarcoma; Treatment Outcome	2019
Nanoparticle augmentation of radiotherapy in sarcoma. The Lancet. Oncology, 2019, Volume: 20, Issue:8 Topics: Hafnium; Humans; Nanoparticles; Oxides; Sarcoma; Soft Tissue Neoplasms	2019